Eosinophil Cationic Protein (ECP) as a Tumor Marker for Malignant Tumors
AssigneeFriedrich-Alexander-Universität Erlangen-Nürnberg
InventorsAlvaro Moreira, Lucie Heinzerling, Gerold Schuler
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of prognosis of survival, of classifying a disease stage, and of selecting the mode of treatment of a patient diagnosed with malignant tumors such as melanoma, of a predictive marker for response to therapy, a kit for determination of the level of eosinophil cationic protein (ECP) in a sample of a tumor patient, such as a melanoma patient, and the use of this kit for methods of prognosis of survival, of classifying a disease stage and of selecting the mode of treatment and monitoring disease and response to treatment of a patient diagnosed with malignant tumors such as melanoma.
Claims20
A method of assessing the status of a patient with a malignant tumor or melanoma, the method comprising determining the level of expression or concentration of eosinophil granule protein or eosinophil cationic protein (ECP) in a sample of the patient.
(canceled)
A kit for in vitro determination of the level of eosinophil granule proteins or mRNA of eosinophil granule proteins or cationic protein (ECP) or ECP mRNA, in a sample of a cancer patient.
Dependencies are inferred from the claim text.